Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $8.80 Average Target Price from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received an average rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.80.

PYXS has been the topic of several research reports. Jefferies Financial Group reissued a “buy” rating and issued a $10.00 target price on shares of Pyxis Oncology in a research report on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, May 16th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PYXS. StemPoint Capital LP purchased a new position in Pyxis Oncology during the first quarter valued at approximately $7,643,000. Ikarian Capital LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter valued at $7,082,000. Vanguard Group Inc. boosted its holdings in Pyxis Oncology by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after buying an additional 94,740 shares during the period. abrdn plc purchased a new stake in Pyxis Oncology in the 4th quarter worth $1,275,000. Finally, Vestal Point Capital LP bought a new stake in Pyxis Oncology during the fourth quarter valued at about $792,000. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Stock Up 7.4 %

PYXS opened at $3.48 on Tuesday. Pyxis Oncology has a twelve month low of $1.35 and a twelve month high of $6.85. The firm has a 50 day moving average price of $3.54 and a 200-day moving average price of $4.09. The stock has a market capitalization of $204.94 million, a price-to-earnings ratio of -2.56 and a beta of 1.28.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Saturday, May 11th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to the consensus estimate of $4.25 million. As a group, analysts expect that Pyxis Oncology will post -1.09 earnings per share for the current year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.